Latest filing published 17 May 2022 for TFF Pharmaceuticals, Inc., €73k.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Glenn R. Mattes: trading record in brief
Glenn R. Mattes (chief executive) discloses dealings in 2 companies, chiefly TFF Pharmaceuticals, Inc. and Arno Therapeutics, Inc. We count 22 filings; the first trade dates from 27 March 2013 and the latest from 16 May 2022.
Both buying and selling appear: 6 purchases worth €269k, against 6 sales worth €3.6M. The amount is not disclosed for 1 filing. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 1 share grant and 5 option exercises. In 2022 alone, the filings show 1 purchase and no sales.
A typical purchase (the median) is worth €45k. On 3 out of 3 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.
Most recently, on 17 May 2022, the filings show an open-market purchase worth €73k in TFF Pharmaceuticals, Inc. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Glenn R. Mattes
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 16,000 shares@ US$4.7854.8% of flowCommon StockSEC:0001213900-22-027791:0Canonical exit: 14 Aug 2022 (T+90)
- 10,000 shares@ US$7.1045.2% of flowCommon StockSEC:0001213900-21-048369:0Canonical exit: 15 Dec 2021 (T+90)
- 50,000 shares@ US$2.502.4% of flowCommon StockSEC:0001213900-21-016183:0
- 50,000 shares@ US$17.0416.3% of flowCommon StockSEC:0001213900-21-016183:1
- 40,000 shares@ US$2.501.9% of flowCommon StockSEC:0001213900-21-010415:0
- 40,000 shares@ US$16.8212.6% of flowCommon StockSEC:0001213900-21-010415:1
- 3,000 shares@ US$17.001.0% of flowCommon StockSEC:0001213900-21-003298:0
- 40,000 shares@ US$2.501.9% of flowCommon StockSEC:0001213900-21-003298:1
- 40,000 shares@ US$17.5113.1% of flowCommon StockSEC:0001213900-21-003298:2
- 30,000 shares@ US$2.502.8% of flowCommon StockSEC:0001213900-20-045177:0
- 30,000 shares@ US$15.3317.3% of flowCommon StockSEC:0001213900-20-045177:1
- 108,830 shares@ US$2.5010.5% of flowCommon StockSEC:0001213900-20-037057:0
- 108,830 shares@ US$14.99563.2% of flowCommon StockSEC:0001213900-20-037057:1
- 10,000 shares@ US$5.002.0% of flowCommon StockSEC:0001213900-19-021417:0Canonical exit: 23 Jan 2020 (T+90)
- 22,218 shares@ US$2.40Common StockSEC:0000914190-13-000751:0
- 1,666 shares@ US$2.40Common StockSEC:0000914190-13-000751:1
- 20,833 sharesCommon StockSEC:0000914190-13-000751:2Canonical exit: 27 Jan 2014 (T+90)
- 3,222 shares@ US$0.30Common StockSEC:0000914190-13-000348:0
- 3,333 shares@ US$0.30Common StockSEC:0000914190-13-000309:0
- 3,333 shares@ US$0.30Common StockSEC:0000914190-13-000247:0
20 of 20 declarations